Drug intelligence / Profile preview

RG1511

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RG1511 is a drug candidate that was investigated by Hoffmann-La Roche for the treatment of Type 2 Diabetes Mellitus. It underwent a Phase 1 multiple ascending dose study to evaluate its pharmacokinetics, pharmacodynamics, safety, and tolerability in patients with Type 2 Diabetes Mellitus. The specific mechanism of action for RG1511 has not been publicly disclosed. Development appears to have been terminated after this initial phase.

Beyond the preview

Go deeper on RG1511.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG1511.

Explore the full profile